3
Announcements
Trials
Browse
Landscape
Status
Completed
42
Terminated
12
Unknown
9
Withdrawn
3
Suspended
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
6
Leukemia, Myeloid, Acute
3
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Locally Advanced Thyroid Gland Carcinoma
1
Liver Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
HCC
1
Fibrolamellar hepatocellular carcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Bevacizumab
9
pembrolizumab
5
lenvatinib
5
durvalumab
5
atezolizumab
5
tremelimumab
3
fludarabine
3
camrelizumab
3
apatinib
3
Ipilimumab
3
Cyclophosphamide
3
regorafenib
2
Riluzole
2
Radiotherapy
2
Nivolumab
2
Magnetic Resonance Imaging
2
Idarubicin
2
Blood Specimen Collection
2
Biopsy
2
yttrium chloride
1
trastuzumab deruxtecan
1
spartalizumab
1
sintilimab
1
pertuzumab
1
ferric carboxymaltose
1
epigallocatechin gallate
1
donafenib
1
cemiplimab
1
brodalumab
1
Yttrium-90
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Liver Neoplasms
×
Sorafenib
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled